Crohn’s & Colitis Congress™

Sessions Speakers Exhibitors Floor Plan Buzz
Search

Sessions (24)

15 - DISRUPTION OF FOXP3-EZH2 INTERACTION BY GENETIC MUTATION OR SIGNALING-INDUCED INACTIVATION REPRESENTS A NOVEL PATHOBIOLOGICAL MECHANISM IN INFLAMMATORY BOWEL DISEASE (Room Pinyon 1/2)

20 Jan 18
8:00 AM - 8:07 AM

Tracks: Clinical and Research Challenges, Session III

Speaker(s): Adebowale Bamidele
Background: While FOXP3+ regulatory T cell (Treg) dysfunction has been linked to human inflammatory bowel disease (IBD), molecular mechanisms for d... More...

Question and Answer (Room Pinyon 1/2)

20 Jan 18
9:30 AM - 9:40 AM

Tracks: Session III

More...

20 - ETROLIZUMAB IMPROVED ENDOSCOPIC SCORE, PATIENT-REPORTED OUTCOMES, AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE UC WHO HAD FAILED TNF ANTAGONIST THERAPY: THE HICKORY OPEN-LABEL INDUCTION (OLI) COHORT (Room Pinyon 4/5)

20 Jan 18
8:00 AM - 8:07 AM

Tracks: Clinical and Research Challenges, Session III

Speaker(s): David Rubin MD, FACG, AGAF, FACP, FASGE
Background: Patients with ulcerative colitis (UC) who have experienced failure of TNF antagonist (aTNF) therapy are a difficult-to-treat populatio... More...

Question and Answer (Room Pinyon 4/5)

20 Jan 18
11:50 AM - 12:00 PM

Tracks: Session III

More...

Basic Quick Shots Breakout (Room Pinyon 1/2)

20 Jan 18
8:00 AM - 8:35 AM

Tracks: Session III

Speaker(s): Matthew Grisham
More...

Clincial Quick Shots Breakout (Room Pinyon 4/5)

20 Jan 18
8:00 AM - 8:35 AM

Tracks: Session III

Speaker(s): Meenakshi Bewtra, MD, PhD, MPH
More...

16 - GENETIC ANALYSIS IDENTIFIED NOVEL LOCI ASSOCIATED WITH IBD (Room Pinyon 1/2)

20 Jan 18
8:07 AM - 8:14 AM

Tracks: Clinical and Research Challenges, Session III

Speaker(s): Dalin Li
Introduction: More than 200 genetic loci have been identified in Inflammatory Bowel Disease (IBD). However, those loci do not explain the full here... More...

21 - WHAT IS THE MOST COST-EFFECTIVE POSITION OF VEDOLIZUMAB IN THE CURRENT TREATMENT ALGORITHM OF ULCERATIVE COLITIS? (Room Pinyon 4/5)

20 Jan 18
8:07 AM - 8:14 AM

Tracks: Clinical and Research Challenges, Session III

Speaker(s): Frank Scott
Background: There are limited data guiding providers and payers on the most cost-effective position for vedolizumab (VDZ) in current ulcerative col... More...

17 - SINGLE-CELL SEQUENCING OF CREEPING FAT IN CROHN’S DISEASE REVEALS DISTINCT IMMUNE CLUSTERS AND CELLULAR RESTRUCTURING IN THE PRESENCE OF LIVE BACTERIA AND FUNGI (Room Pinyon 1/2)

20 Jan 18
8:14 AM - 8:21 AM

Tracks: Management of Complicated IBD, Session III

Speaker(s): Suzanne Devkota
Crohn’s Disease and ulcerative colitis present distinct characteristics, one being the expansion of mesenteric adipose tissue (MAT) surroundi... More...

22 - PERSISTENT OPIOID USE AND HEALTHCARE UTILIZATION AMONG ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES (Room Pinyon 4/5)

20 Jan 18
8:14 AM - 8:21 AM

Tracks: Clinical and Research Challenges, Session III

Speaker(s): Ana Vanessa Wren
Background: Opioids are commonly prescribed for temporary pain relief among individuals with inflammatory bowel disease (IBD); however, the efficac... More...

18 - MYELOID VITAMIN D RECEPTOR SIGNALING REGULATES PANETH CELL FUNCTION AND INTESTINAL HOMEOSTASIS

20 Jan 18
8:21 AM - 8:28 AM

Tracks: Clinical and Research Challenges, Session III

Speaker(s): Danika Bakke
Background: Vitamin D receptor (VDR) regulates the biological actions of the active vitamin D metabolite, 1α,25-dihydroxyvitamin D3. Evidence... More...

23 - EMERGENT COLECTOMY RATES DECREASED WHILE ELECTIVE IPAA RATES WERE STABLE OVER TIME: A NATIONWIDE INPATIENT SAMPLE STUDY (Room Pinyon 4/5)

20 Jan 18
8:21 AM - 8:28 AM

Tracks: Management of Complicated IBD, Session III

Speaker(s): Ryan Ungaro
Background: Despite advances in medical therapy for UC, many patients still need surgery. Data on UC colectomy rates in the United States are limit... More...

24 - HIGHER BODY MASS INDEX IS ASSOCIATED WITH INCREASED RISK OF TREATMENT FAILURE AND SURGERY IN BIOLOGIC-TREATED PATIENTS WITH ULCERATIVE COLITIS (Room Pinyon 4/5)

20 Jan 18
8:28 AM - 8:35 AM

Tracks: Management of Complicated IBD, Session III

Speaker(s): Soumya Kurnool
Background: Though pharmacokinetic studies suggest accelerated biologic drug clearance with increasing body weight, evidence of obesity’s imp... More...

Clinical Challenges You Face Every Day (Room Pinyon 4/5)

20 Jan 18
8:35 AM - 9:40 AM

Tracks: Session III

Speaker(s): Douglas Wolf MD ; Eva Szigethy MD, PhD ; KT Park MD, MS ; Phillip Minar MD ; Robert Burakoff MD, MPH, AGAF
Case 1: How Do We Reduce Narcotic Use? Case 2: Access to Care: How to Get the Care the Patient Needs Click or tap HERE to download the cases. More...

Translational Research Breakout (Room Pinyon 1/2)

20 Jan 18
8:35 AM - 9:40 AM

Tracks: Session III

Speaker(s): Brent Polk MD, AGAF ; David Rubin MD, FACG, AGAF, FACP, FASGE
More...

Advancing Findings in Immunology (Room Pinyon 1/2)

20 Jan 18
8:55 AM - 9:10 AM

Tracks: Session III

Speaker(s): Clara Abraham MD
More...

25 - MUTATIONS IN STXBP3 CONTRIBUTE TO VERY EARLY ONSET OF IBD, IMMUNODEFICIENCY AND HEARING LOSS (Room Pinyon 1/2)

20 Jan 18
9:10 AM - 9:20 AM

Tracks: Clinical and Research Challenges, Session III

Very early-onset inflammatory bowel disease (VEO-IBD), defined by the onset of IBD before 6 years of age, is often associated with more severe and ... More...

26 - A HUMAN-ASSOCIATED FECAL TRANSPLANTATION MOUSE MODEL TO STUDY THE FUNCTIONALITY OF THE GUT MICROBIOME (Room Pinyon 1/2)

20 Jan 18
9:20 AM - 9:30 AM

Tracks: Clinical and Research Challenges, Session III

Background: We performed a series of fecal microbiota transplantation (FMT) experiments to determine the functional persistence of human microbiota... More...

27 - CLINICAL AND GENOMIC CORRELATES OF NEUTROPHIL GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR SIGNALING IN PEDIATRIC CROHN DISEASE (Room Pinyon 4/5)

20 Jan 18
10:30 AM - 10:40 AM

Tracks: Clinical and Research Challenges, Session III

Speaker(s): David Okou
Background and Aims: Neutralizing Granulocyte-Macrophage Colony Stimulating Factor auto-antibodies (GMAb) suppress neutrophil extrinsic GM-CSF sign... More...

28 - CHARACTERISTICS AND OUTCOMES OF PROSPECTIVELY REPORTED PREGNANCIES EXPOSED TO CERTOLIZUMAB PEGOL FROM A SAFETY DATABASE (Room Pinyon 4/5)

20 Jan 18
11:00 AM - 11:10 AM

Tracks: Clinical and Research Challenges, Session III

Speaker(s): Anita Afzali
Background: Anti-tumor necrosis factor (anti-TNF) medications are effective in controlling chronic inflammatory diseases, but information about pre... More...

Basic Theme (Room Pinyon 4/5)

20 Jan 18
11:10 AM - 11:30 AM

Tracks: Session III

Speaker(s): Fabio Cominelli MD, PhD
More...

Highlight: One Basic Research Theme, One Clinical Research Theme in 2017 (Room Pinyon 4/5)

20 Jan 18
11:10 AM - 11:50 AM

Tracks: Session III

Speaker(s): Bruce Sands MD, MS, AGAF ; Fabio Cominelli MD, PhD
More...

Clinical Theme (Room Pinyon 4/5)

20 Jan 18
11:30 AM - 11:50 AM

Tracks: Session III

Speaker(s): Bruce Sands MD, MS, AGAF
More...